Liu Wen-Ming, Li Xiao-Bing
Department of Gastrointestinal Surgery, The First People's Hospital of Tianmen, Tianmen 431700, Hubei Province, China.
Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, Hubei Province, China.
World J Clin Oncol. 2025 May 24;16(5):102223. doi: 10.5306/wjco.v16.i5.102223.
Metastatic colorectal cancer (mCRC) patients with mutation have a poor prognosis despite the implementation of multiple treatment strategies. The integration of traditional Chinese medicine with Western medicine in treating mutant mCRC has garnered increasing attention. Recent studies indicate that combining traditional Chinese and modern Western medical approaches not only extend survival but also reduces the risk of mortality in patients with mutant mCRC. This approach is particularly effective for colorectal cancer patients who have right-sided colon involvement, liver metastasis, or a history of radiotherapy or chemotherapy. In this treatment combination, traditional Chinese medicine may offer symptomatic relief and improve quality of life, while Western medicine targets the disease more aggressively with advanced pharmacological agents. Ongoing research is crucial to further elucidate the mechanisms underlying these benefits and to optimize treatment protocols.
尽管实施了多种治疗策略,但携带[具体突变名称]突变的转移性结直肠癌(mCRC)患者预后较差。中西医结合治疗[具体突变名称]突变型mCRC日益受到关注。最近的研究表明,将传统中医与现代西医方法相结合,不仅可以延长[具体突变名称]突变型mCRC患者的生存期,还能降低其死亡风险。这种方法对右侧结肠受累、肝转移或有放疗或化疗史的结直肠癌患者尤为有效。在这种联合治疗中,中药可能缓解症状并改善生活质量,而西药则使用先进的药物更积极地针对疾病。持续的研究对于进一步阐明这些益处背后的机制以及优化治疗方案至关重要。
World J Clin Oncol. 2025-5-24
World J Clin Oncol. 2025-1-24
Ther Adv Med Oncol. 2021-2-22
World J Clin Oncol. 2025-1-24
JAMA Netw Open. 2024-7-1
Front Pharmacol. 2023-10-20
Phytomedicine. 2024-1
Phytomedicine. 2023-7-25